Dong Zhouzhou, Shi Linhui, Ye Longqiang, Xu Zhiwei, Zhou Li
Department of Intensive Care Unit, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo 315040, Zhejiang, China (Dong ZZ, Shi LH, Ye LQ, Xu ZW); Department of Infectious Disease, Ningbo Medical Center Lihuili Eastern Hospital, Ningbo 315040, Zhejiang, China (Zhou L). Corresponding author: Zhou Li, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018 Nov;30(11):1056-1060. doi: 10.3760/cma.j.issn.2095-4352.2018.011.009.
To analyze the risk factors of renal replacement therapy (RRT) in acute kidney injury (AKI) patients after liver transplantation, and to investigate the prognosis effect of initial RRT treatment time.
Clinical data of 132 recipients undergoing organ donation for cardiac death (DCD) allograft orthotopic liver transplantation admitted to Ningbo Medical Center Lihuili Hospital and Ningbo Medical Center Lihuili Eastern Hospital from July 2014 to July 2018 was retrospectively analyzed. AKI was defined and staged by the criteria of Kidney Disease Improving Global Outcomes (KDIGO) guideline in the first 7 days. According to the implementation of RRT, the patients were divided into non-RRT group and RRT group. The differences in gender, age, body mass index (BMI), model for end-stage liver disease with serum sodium (MELD-Na) score, serum creatinine (SCr), and intraoperative norepinephrine (NE) dose, blood loss, fluid infusion, anhepatic phase time, duration of operation between two groups were compared. The statistically significant risk factors of AKI found by univariate analysis were selected and analyzed to find independent risk factors of RRT in AKI patients after liver transplantation with multivariate Logistic regression analysis. The receiver operating characteristic (ROC) curve was drawn to evaluate the test efficiency of all risk factors of RRT implementation. According to the implementation of RRT on KDIGO stage-2, all the patients on KDIGO stage-2 and stage-3 were divided into early group (initial RRT on KDIGO stage-2) and delayed group (including self-improvement without RRT on KDIGO stage-2 and initial RRT on KDIGO stage-3). The duration of mechanical ventilation, the length of intensive care unit (ICU) stay, AKI duration, incidence of catheter related bloodstream infection (CRBSI) and 28-day mortality were compared between the two groups.
All 132 receptors were enrolled in the final analysis, and 77 patients developed AKI, accounting for 58.3%, among which 52 cases were in RRT group (67.5%) and 25 were in non-RRT group (32.5%). As shown by univariate analysis, the MELD-Na score (21.6±4.4 vs. 18.0±4.3), intraoperative NE dose (μg×kg×h: 7.5±1.2 vs. 5.2±1.7), blood loss [mL: 3 000 (2 200, 4 000) vs. 2 600 (1 800, 3 200)], fluid infusion [mL: 6 400 (4 500, 7 800) vs. 5 600 (4 200, 6 800)], and anhepatic period (minutes: 65.6±4.5 vs. 63.0±5.0) were significantly increased in RRT group as compared with those in non-RRT group (all P < 0.05). There was no significant difference in gender, age, BMI, SCr before operation or the duration of operation. It was shown by multivariate Logistic regression analysis that MELD-Na score before operation [odds ratio (OR) = 1.398, 95% confidence interval (95%CI) = 1.062-1.841, P = 0.017], intraoperative NE dose (OR = 4.724, 95%CI = 2.036-10.961, P = 0.000) and fluid infusion (OR = 1.002, 95%CI = 1.001-1.004, P = 0.010) were independent risk factors of RRT implementation in AKI patients after liver transplantation. It was shown by ROC curve analysis that the area under the ROC curve (AUC) of MELD-Na score, NE dose and fluid infusion for predicting the implementation of RRT in AKI patients after liver transplantation was 0.719, 0.867, and 0.670, respectively, which suggesting that NE dose had moderate predictive value, but MELD-Na score and fluid infusion had low predicative value. When the optimal cut-off value of NE dose was 6.5 μg×kg×h, the sensitivity was 84.6% and the specificity was 80.0%. The 28-day mortality was both 0 in early group (n = 25) and delayed group (n = 39). Compared with the early group, the duration of mechanical ventilation (hours: 41.0±1.0 vs. 35.8±6.7) and the length of ICU stay (hours: 98.8±6.6 vs. 94.2±7.3) were significantly increased in delayed group (both P < 0.05), there was no significant difference in AKI duration (days: 11.8±4.2 vs. 10.6±4.9) or the incidence of CRBSI [5.1% (2/39) vs. 4.0% (1/25), both P > 0.05].
MELD-Na score, intraoperative NE dose and fluid infusion were the independent risk factors of RRT implementation in AKI patients after liver transplantation. NE dose had moderate predictive value, but MELD-Na score and fluid infusion had low predicative value. Initial RRT on KDIGO stage-2 could reduce the duration of mechanical ventilation and the length of ICU stay.
分析肝移植术后急性肾损伤(AKI)患者行肾脏替代治疗(RRT)的危险因素,并探讨首次RRT治疗时机对预后的影响。
回顾性分析2014年7月至2018年7月在宁波市医疗中心李惠利医院及宁波市医疗中心李惠利东部医院接受心死亡器官捐献(DCD)同种异体原位肝移植的132例受者的临床资料。术后第1个7天内根据改善全球肾脏病预后组织(KDIGO)指南标准定义并分期AKI。根据是否实施RRT,将患者分为非RRT组和RRT组。比较两组患者的性别、年龄、体重指数(BMI)、终末期肝病伴血清钠模型(MELD-Na)评分、血清肌酐(SCr)、术中去甲肾上腺素(NE)用量、失血量、液体入量、无肝期时间、手术时长。对单因素分析中发现的AKI的有统计学意义的危险因素进行多因素Logistic回归分析,以找出肝移植术后AKI患者行RRT的独立危险因素。绘制受试者工作特征(ROC)曲线,评估RRT实施的所有危险因素的检验效能。根据KDIGO 2期时RRT的实施情况,将所有KDIGO 2期和3期患者分为早期组(KDIGO 2期时首次行RRT)和延迟组(包括KDIGO 2期时未行RRT自行好转及KDIGO 3期时首次行RRT)。比较两组患者的机械通气时间、重症监护病房(ICU)住院时间、AKI持续时间、导管相关血流感染(CRBSI)发生率及28天死亡率。
132例受者均纳入最终分析,77例发生AKI,占58.3%,其中RRT组52例(67.5%),非RRT组25例(32.5%)。单因素分析结果显示,与非RRT组相比,RRT组的MELD-Na评分(21.6±4.4比18.0±4.3)、术中NE用量(μg×kg×h:7.5±1.2比5.2±1.7)、失血量[mL:3 000(2 200,4 000)比2 600(1 800,3 200)]、液体入量[mL:6 400(4 500,7 800)比 5 600(4 200,6 800)]及无肝期(分钟:65.6±4.5比63.0±5.0)均显著增加(均P<0.05)。两组患者的性别、年龄、BMI、术前SCr及手术时长比较,差异均无统计学意义。多因素Logistic回归分析结果显示,术前MELD-Na评分[比值比(OR)=1.398,95%置信区间(95%CI)=1.0621.841,P=0.017]、术中NE用量(OR=4.724,95%CI=2.03610.961,P=0.000)及液体入量(OR=1.002,95%CI=1.001~1.004,P=0.010)是肝移植术后AKI患者行RRT的独立危险因素。ROC曲线分析结果显示,MELD-Na评分、NE用量及液体入量预测肝移植术后AKI患者行RRT的ROC曲线下面积(AUC)分别为0.719、0.867及0.670,提示NE用量有中等预测价值,而MELD-Na评分及液体入量预测价值较低。当NE用量的最佳截断值为6.5 μg×kg×h时,敏感度为84.6%,特异度为80.0%。早期组(n=25)和延迟组(n=39)的28天死亡率均为0。与早期组比较,延迟组的机械通气时间(小时:41.0±1.0比35.8±6.7)及ICU住院时间(小时:98.8±6.6比94.2±7.3)均显著延长(均P<0.05),AKI持续时间(天:11.8±4.2比10.6±4.9)及CRBSI发生率[5.1%(2/39)比4.0%(1/25)]比较,差异均无统计学意义(均P>0.05)。
MELD-Na评分、术中NE用量及液体入量是肝移植术后AKI患者行RRT的独立危险因素。NE用量有中等预测价值,而MELD-Na评分及液体入量预测价值较低。KDIGO 2期时首次行RRT可缩短机械通气时间及ICU住院时间。